Ph.D., Chief Business Development Officer, Adaptive Biotechnologies
Biography
Dr. Sharon Benzeno is the Chief Business Development Officer and leads the Drug Discovery group at Adaptive. Sharon oversees the use of the company’s immune medicine platform for novel drug discovery, including TCR discovery to inform next-generation cellular therapy, antibody discovery, and vaccines. Before joining Adaptive in 2014, Sharon was Senior Director at Elsevier Inc., a healthcare informatics company. Prior to Elsevier, Sharon co-led the oncology business unit at Capgemini SE, a consulting and technology services company. Sharon came to Elsevier from Capgemini, where she held a variety of management roles at AstraZeneca plc. Sharon holds a PhD in Biomedical Sciences from New York University School of Medicine, an MBA in Finance and Leadership from New York University Stern School of Business and a BA in Biochemistry from New York University. Sharon completed a postdoctoral fellowship in cancer biology at the University of Pennsylvania Abramson Cancer Center.
Session Abstract – PMWC 2022 Silicon Valley
Track 1 - June 29 11.00 A.M.-12.00 P.M.
Panel
Session Abstract – PMWC 2022 Silicon Valley
Track 1 - June 29 1.00 P.M.-1.45 P.M.
For truly personalized cell and gene therapies to become standard of care, we must continue to leverage and successfully implement advances in science, technology, automation and digitization to scale the process and shorten the time it takes to get lifesaving medicines to patients in need.
Session Abstract – PMWC 2022 Silicon Valley
Track 1 - June 29 1.00 P.M.-1.45 P.M.
Track Chair:
Ira Mellman, Genentech
Human cells have been successfully used as treatment for blood cancers for decades but translating the promise to cell-based treatment for solid tumors has been slow. The advent of gene-editing techniques such as CRISPR, coupled with advances in our understanding of immunology and optimization of growing, manufacturing, transporting, storing, and handling specialized biological samples and materials is transforming the cell therapy field. We will hear in this session about some of the most promising work in the field, as well as the challenges in overcoming resistance
-
Sessions:
- Recent Advances in Cell-based Therapy (PANEL)
Session Chair: Sascha Rutz, Genentech
- Susie Jun, ArsenalBio
- Elliot Norry, Adaptimmune
- Tina Albertson, Lyell
- Hy Levitsky, Century Therapeutics - Patentability of Immunotherapies—Latest Developments
- Janet Xiao, Morrison & Foerster LLP - Cell-based Therapy Challenges (PANEL)
Session Chair: Sharon Benzeno, Adaptive Biotechnologies
- Arati Rao, PACT Pharma
- Hy Levitsky, Century Therapeutics
- Susie Jun, ArsenalBio - Next-generation Supply Chain For Cell & Gene Therapies (PANEL)
Session Chair: Sharon Benzeno, Adaptive Biotechnologies
- Tim Moore, Pact Pharma
- Heidi Hunter, Cardinal Health - Advances in Multi-Omic Spatial Profiling
Session Chair: Michael Rhodes, Nanostring
- Chris Corless, OHSU
- Biomarkers to Guide Immunotherapy
Session Chair: Danny Wells, ImmunAI
- Sanjeev Mariathasan, Genentech
- Klaus Lindpaintner, InterVenn Bioscience
- Lacey Padron, PICI - NaNots: A New Class of Immunotherapy
- Lou Hawthorne, Nanotics - Engineered Therapeutics (PANEL)
Session Chair: Paul Parren, Lava Therapeutics
- Sonja Schrepfer, UCSF
- Greg Lazar, Genentech
